PURPOSE: Allogeneic stem-cell transplantation (SCT) induces long-term remission in a fraction of patients with high-risk chronic lymphocytic leukemia (CLL) or Richter's transformation (RT). Our purpose was to determine the outcomes of patients whose disease progressed after allogeneic SCT. PATIENTS AND METHODS: We retrospectively analyzed the outcomes of 72 patients (52 with CLL and 20 with RT) who underwent allogeneic SCT between 1998 and 2011 and had documented progression after transplantation. Twenty-two (31%) never had a response, and 50 (69%) had a response but experienced relapse after a median of 7 months (range, 2 to 85 months). Forty-eight patients who were receiving or were candidates to receive post-SCT cell-based therapies were not included in this analysis. RESULTS: The median age at time of transplantation was 58 years (range, 30 to 72 years). Sixty-two patients (86%) received more than two treatment regimens and 37 (51%) received more than three treatment regimens before SCT. Sixty-six patients (92%) had active disease at the time of transplantation. The 2- and 5-year survival rates were 67% and 38% (patients with CLL) and 36% and 0% (patients with RT). The patients who developed acute or chronic graft-versus-host disease had a longer overall survival (OS; P = .05). In a multivariable analysis, RT or low hemoglobin at the time of SCT predicted shorter OS. Chronic graft-versus-host disease and an initial response to SCT predicted longer OS. CONCLUSION: Patients with CLL in whom allogeneic SCT fails may have a response to and benefit from salvage therapies, and their prognosis is relatively good.
PURPOSE: Allogeneic stem-cell transplantation (SCT) induces long-term remission in a fraction of patients with high-risk chronic lymphocytic leukemia (CLL) or Richter's transformation (RT). Our purpose was to determine the outcomes of patients whose disease progressed after allogeneic SCT. PATIENTS AND METHODS: We retrospectively analyzed the outcomes of 72 patients (52 with CLL and 20 with RT) who underwent allogeneic SCT between 1998 and 2011 and had documented progression after transplantation. Twenty-two (31%) never had a response, and 50 (69%) had a response but experienced relapse after a median of 7 months (range, 2 to 85 months). Forty-eight patients who were receiving or were candidates to receive post-SCT cell-based therapies were not included in this analysis. RESULTS: The median age at time of transplantation was 58 years (range, 30 to 72 years). Sixty-two patients (86%) received more than two treatment regimens and 37 (51%) received more than three treatment regimens before SCT. Sixty-six patients (92%) had active disease at the time of transplantation. The 2- and 5-year survival rates were 67% and 38% (patients with CLL) and 36% and 0% (patients with RT). The patients who developed acute or chronic graft-versus-host disease had a longer overall survival (OS; P = .05). In a multivariable analysis, RT or low hemoglobin at the time of SCT predicted shorter OS. Chronic graft-versus-host disease and an initial response to SCT predicted longer OS. CONCLUSION:Patients with CLL in whom allogeneic SCT fails may have a response to and benefit from salvage therapies, and their prognosis is relatively good.
Authors: S N Rabinowe; R J Soiffer; J G Gribben; H Daley; A S Freedman; J Daley; K Pesek; D Neuberg; G Pinkus; P R Leavitt Journal: Blood Date: 1993-08-15 Impact factor: 22.113
Authors: John G Gribben; David Zahrieh; Katherine Stephans; Lini Bartlett-Pandite; Edwin P Alyea; David C Fisher; Arnold S Freedman; Peter Mauch; Robert Schlossman; Lecia V Sequist; Robert J Soiffer; Blossom Marshall; Donna Neuberg; Jerome Ritz; Lee M Nadler Journal: Blood Date: 2005-08-30 Impact factor: 22.113
Authors: P Dreger; R Brand; D Milligan; P Corradini; J Finke; G Lambertenghi Deliliers; R Martino; N Russell; A van Biezen; M Michallet; D Niederwieser Journal: Leukemia Date: 2005-06 Impact factor: 11.528
Authors: Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian Journal: J Clin Oncol Date: 2005-03-14 Impact factor: 44.544
Authors: I F Khouri; D Przepiorka; K van Besien; S O'Brien; J L Palmer; S Lerner; R C Mehra; H M Vriesendorp; B S Andersson; S Giralt; M Körbling; M J Keating; R E Champlin Journal: Br J Haematol Date: 1997-05 Impact factor: 6.998
Authors: I F Khouri; M Keating; M Körbling; D Przepiorka; P Anderlini; S O'Brien; S Giralt; C Ippoliti; B von Wolff; J Gajewski; M Donato; D Claxton; N Ueno; B Andersson; A Gee; R Champlin Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Matthias Ritgen; Stephan Stilgenbauer; Nils von Neuhoff; Andreas Humpe; Monika Brüggemann; Christiane Pott; Thorsten Raff; Alexander Kröber; Donald Bunjes; Richard Schlenk; Norbert Schmitz; Hartmut Döhner; Michael Kneba; Peter Dreger Journal: Blood Date: 2004-06-17 Impact factor: 22.113
Authors: I F Khouri; M J Keating; H M Vriesendorp; C L Reading; D Przepiorka; Y O Huh; B S Andersson; K W van Besien; R C Mehra; S A Giralt Journal: J Clin Oncol Date: 1994-04 Impact factor: 44.544
Authors: C S Link; R Teipel; F Heidenreich; E Rücker-Braun; M Schmiedgen; J Reinhardt; U Oelschlägel; M von Bonin; J M Middeke; A Muetherig; K Trautmann-Grill; U Platzbecker; M Bornhäuser; J Schetelig Journal: Bone Marrow Transplant Date: 2016-01-11 Impact factor: 5.483
Authors: Mauricette Michallet; Peter Dreger; Mohamad Sobh; Linda Koster; Jennifer Hoek; Ariane Boumendil; Christof Scheid; Christopher P Fox; Gerald Wulf; William Krüger; Michel van Gelder; Paolo Corradini; Domenico Russo; Jakob Passweg; Hélène Schoemans; Wolfgang Bethge; Nicolaas Schaap; Jan Cornelissen; Paul Browne; Nadira Durakovic; Lutz Muller; Silvia Montoto; Nicolaus Kroger; Johannes Schetelig Journal: Bone Marrow Transplant Date: 2019-11-07 Impact factor: 5.483
Authors: M Hahn; S Böttcher; S Dietrich; U Hegenbart; M Rieger; P Stadtherr; A Bondong; R Schulz; M Ritgen; T Schmitt; T H Tran; M Görner; I Herth; T Luft; S Schönland; M Witzens-Harig; T Zenz; M Kneba; A D Ho; P Dreger Journal: Bone Marrow Transplant Date: 2015-07-06 Impact factor: 5.483
Authors: Philip A Thompson; Francesco Stingo; Michael J Keating; William G Wierda; Susan M O'Brien; Zeev Estrov; Celina Ledesma; Katayoun Rezvani; Muzaffar Qazilbash; Nina Shah; Simrit Parmar; Uday Popat; Paolo Anderlini; Nieto Yago; Stefan O Ciurea; Partow Kebriaei; Richard Champlin; Elizabeth J Shpall; Chitra M Hosing Journal: Br J Haematol Date: 2017-03-14 Impact factor: 6.998
Authors: Othman Al-Sawaf; Carmen Diana Herling; Udo Holtick; Christoph Scheid; Paula Cramer; Stephanie Sasse; Bastian von Tresckow; Armin Tuchscherer; Kirsten Fischer; Barbara Eichhorst; Michael Hallek; Lukas P Frenzel Journal: Haematologica Date: 2019-02-21 Impact factor: 9.941
Authors: Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos Journal: Blood Date: 2016-11-01 Impact factor: 22.113